Herombopag
Conditions
Brief summary
The objective of this study was to evaluate the efficacy and safety of Herombopag in the treatment of elderly patients with ITP.
Detailed description
This is a single-arm, prospective clinical study to evaluate the efficacy and safety of herombopag in the treatment of elderly patients with ITP. The study will include 80 patients. Screening of patients will be 2 weeks after the longest period, to enter after the treatment period, accept the herombopag 5 mg, once daily, on an empty stomach, oral medication can be eating only 2 hours, and 24 weeks of treatment, and adjust the dosage according to the platelet count. If patients do not respond to treatment after 8 weeks, it is recommended to withdraw from the study and continue safety visits for 4 weeks. During treatment, the patient continues treatment until the investigator assesses the occurrence of intolerable toxicity, disease progression, withdrawal of informed consent, or other discontinuation criteria specified in the protocol (whichever occurs first). Follow-up treatment for patients who withdraw from treatment due to safety or ineffectiveness is determined by the investigator according to clinical practice. Safety assessment during treatment, including vital signs, physical examination, laboratory examination, etc.; Check your blood routine at least once a week. A 4-week safety visit was performed after the final treatment.
Interventions
The patient received herombopag 5mg/d at the beginning of the day, was orally taken on an empty stomach in the morning, and could eat 2 hours after taking the drug, once a day for 24 weeks. Investigators will adjust the dosage of herombopag once a week according to the platelet count, with a maximum dosage of 7.5 mg per day. Efficacy and safety were evaluated once a week.
Sponsors
Institute of Hematology & Blood Diseases Hospital, China
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients voluntarily participated in the study and signed informed consent; * Age ≥60 years old, gender unlimited; * ECOG PS ≤2; * Expected survival ≥6 months; * A definitive diagnosis of ITP, including newly diagnosed, chronic, and persistent ITP; * PLT \< 30×109/L for at least two consecutive times with an interval of at least 1 day before medication * Patients with laboratory test results meet the following criteria: a. alanine aminotransferase (ALT) 3.0 x or less normal limit (ULN), aspartate aminotransferase (AST) 3.0 x ULN or less; b. Serum total bilirubin ≤1.5×ULN; c. Serum creatinine ≤1.5×ULN; * The researchers determined that patients could be treated with hexapopal.
Exclusion criteria
* Patients who did not respond to previous treatment with herombopag; * A history of allergy to thrombopoietin receptor agonist (TPO-RA) drugs; * Combined with other important organ dysfunction, such as liver and kidney failure, cardiac insufficiency, etc. * Secondary thrombocytopenia, such as rheumatic immune disease, chronic liver disease, hyperlienism, malignant hematologic disease, bone marrow hematopoietic exhaustion disease (such as AA, MDS), hereditary thrombocytopenia, CVID, drug-induced thrombocytopenia, etc.; * Receive TPO-RA medication within 2 weeks prior to treatment; * Non-steroidal anti-inflammatory drugs (aspirin, salicylate, etc.) and anticoagulants (warfarin, clopidogrel, etc.) should be taken during treatment, which have an impact on platelet function. * There are severe active bleeding symptoms, such as gastrointestinal bleeding, intracranial bleeding, etc. * Severe thrombotic disease, such as transient ischemic attack, myocardial infarction, pulmonary embolism, deep vein thrombosis, and disseminated intravascular coagulation (DIC), occurred within 6 months prior to the screening period; * Have a New York Heart Society (NYHA) Class 3 or 4 congestive heart failure, or have a history of NYHA Class 3/4 congestive heart failure with a left ejection fraction (LVEF) of \< 45% within 4 weeks prior to treatment; * Positive anti-human immunodeficiency virus antibody or anti-treponema pallidum specific antibody; Hepatitis virus positive, such as HBV, HCV, etc. * A history of cirrhosis; * Bone marrow reticulum fiber staining (MF) ≥2 grade; * Have an active infection that is difficult to control; * Have a history of or accompanied by malignant tumors; * Pregnant or lactating women; * Any other conditions that the investigator determines are not suitable for participation in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients with platelet count ≥30×109/L | 8 weeks | Proportion of subjects with a platelet count ≥ 30 × 10\^9/L and at least twice the baseline platelet count without bleeding at week 8 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients with platelet count ≥100×109/L | 8 weeks | Proportion of patients who achieved CR within 8 weeks of treatment |
| Duration from treatment initiation to platelet count ≥30×10^9/L and ≥50×10^9/L | 24 weeks | The time of first Platelet≥30×109/L and ≥50×109/L |
| Sustained response at 24 weeks of treatment | 24 weeks | Sustained response at 24 weeks of treatment defined as 8 weeks after the last visit, at least 6 visits with platelets ≥30×109/L, greater than 2 times of baseline, and no bleeding |
| Proportion of patients with platelet count ≥50×109/L | 8 weeks | Proportion of patients with platelet count ≥50×109/L within 8 weeks of treatment |
| Emergency treatment | 8 weeks | The proportion of subjects who received emergency treatment within 8 weeks and during the entire study period. |
| incidence of treatment-emergent Adverse Events and TRAE | 24 weeks | Incidence, severity, and relationship of treatment emergent adverse events after treatment as assessed by CTCAE v5.0 |
| The change in bleeding score before treatment and 8 weeks after treatment assessed using the world health organization (WHO) bleeding scale | 8 weeks | The change in bleeding score before treatment and 8 weeks after treatment according to the reported World Health Organization's Bleeding Scale. The WHO Bleeding Scale is a measure of bleeding severity with the following grades: grade 0 = no bleeding, grade 1= petechiae, grade 2= mild blood loss, grade 3 = gross blood loss, and grade 4 = debilitating blood loss. |
Countries
China
Contacts
Primary ContactYunfei Chen
Outcome results
None listed